Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MNKD 
MannKind Corp (MNKD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: MNKD (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.43
1 Year Target Price $9.43
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26.59% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.09B USD | Price to earnings Ratio 36 | 1Y Target Price 9.43 |
Price to earnings Ratio 36 | 1Y Target Price 9.43 | ||
Volume (30-day avg) 7 | Beta 1.01 | 52 Weeks Range 3.52 - 7.63 | Updated Date 07/3/2025 |
52 Weeks Range 3.52 - 7.63 | Updated Date 07/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.12% | Operating Margin (TTM) 31.65% |
Management Effectiveness
Return on Assets (TTM) 10.97% | Return on Equity (TTM) - |
Valuation
Trailing PE 36 | Forward PE 24.15 | Enterprise Value 965945924 | Price to Sales(TTM) 3.68 |
Enterprise Value 965945924 | Price to Sales(TTM) 3.68 | ||
Enterprise Value to Revenue 3.25 | Enterprise Value to EBITDA 11.7 | Shares Outstanding 303932992 | Shares Floating 298155088 |
Shares Outstanding 303932992 | Shares Floating 298155088 | ||
Percent Insiders 1.86 | Percent Institutions 58.64 |
Upturn AI SWOT
MannKind Corp
Company Overview
History and Background
MannKind Corp. was founded in 1991. It is a biopharmaceutical company focused on the discovery, development, and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases.
Core Business Areas
- Pulmonary Therapies: Focuses on developing and commercializing therapies for pulmonary diseases.
- Endocrine Therapies: Focuses on therapies addressing endocrine disorders.
- Technosphere Technology: MannKind's proprietary drug formulation platform.
Leadership and Structure
Michael Castagna is the Chief Executive Officer. The company has a typical organizational structure with departments focused on research and development, commercial operations, finance, and administration.
Top Products and Market Share
Key Offerings
- Afrezza: An inhaled insulin product for adults with diabetes mellitus. While precise market share data is difficult to obtain, it competes with injectable insulins from Novo Nordisk (NVO), Eli Lilly (LLY), and Sanofi (SNY). Afrezza is differentiated by its rapid onset and short duration of action. Revenue in 2023 was roughly $60 million. Afrezza competitors include Lantus (Sanofi), Humalog (Eli Lilly), and Novolog (Novo Nordisk)
- Tyvaso DPI: An inhaled dry powder formulation of treprostinil developed in collaboration with United Therapeutics (UTHR) for the treatment of pulmonary hypertension. Tyvaso DPI's competitors include other prostacyclin analogues and PDE5 inhibitors.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and strong competition. The inhaled drug delivery market is growing due to its convenience and effectiveness.
Positioning
MannKind is a niche player focusing on inhaled drug delivery. Its competitive advantage lies in its Technosphere platform, which allows for rapid drug absorption.
Total Addressable Market (TAM)
The estimated TAM for inhaled insulin and pulmonary hypertension therapies is several billion dollars. MannKind is positioned to capture a portion of this TAM through Afrezza and Tyvaso DPI.
Upturn SWOT Analysis
Strengths
- Proprietary Technosphere technology
- Partnership with United Therapeutics
- Rapid onset of action of Afrezza
Weaknesses
- Limited financial resources
- Dependence on a few key products
- History of losses
Opportunities
- Expansion of Afrezza into new markets
- Development of new products using Technosphere technology
- Potential for acquisitions or partnerships
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expiration
Competitors and Market Share
Key Competitors
- NVO
- LLY
- SNY
- UTHR
Competitive Landscape
MannKind competes with larger pharmaceutical companies. Its Technosphere platform offers a competitive advantage, but its financial resources are limited.
Growth Trajectory and Initiatives
Historical Growth: MannKind has experienced fluctuating revenue growth. Recent partnerships and product approvals suggest potential for future growth.
Future Projections: Analyst estimates vary, but generally project revenue growth driven by Afrezza and Tyvaso DPI sales.
Recent Initiatives: Commercial partnerships like with United Therapeutics for Tyvaso DPI, ongoing clinical trials and regulatory submissions.
Summary
MannKind Corp is a biopharmaceutical company with innovative inhaled drug delivery technology. Its strengths lie in its Technosphere platform and partnerships, but it faces challenges due to its limited resources and competition. Recent initiatives and growth in Tyvaso DPI sales show promise. The company needs to carefully manage its finances and expand its product pipeline to achieve sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q)
- Company press releases
- Analyst reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and may vary. Investing in pharmaceutical companies involves risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MannKind Corp
Exchange NASDAQ | Headquaters Danbury, CT, United States | ||
IPO Launch date 2004-07-28 | CEO & Director Dr. Michael E. Castagna Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 403 | Website https://www.mannkindcorp.com |
Full time employees 403 | Website https://www.mannkindcorp.com | ||
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.